Step-by-Step Guide to Reporting SUSARs to EMA via EudraVigilance

In the European Union (EU), pharmacovigilance plays a crucial role in ensuring the safety of subjects enrolled in clinical trials. One of the most critical components of this system is the timely and accurate reporting of Suspected Unexpected Serious Adverse Reactions (SUSARs) to the European Medicines Agency (EMA) via its electronic system, EudraVigilance. This article provides a comprehensive, tutorial-style guide to help clinical trial sponsors, CROs, and regulatory professionals navigate the process of reporting SUSARs to EMA via EudraVigilance, in alignment with EMA and Good Pharmacovigilance Practices (GVP) guidelines.

What Is a SUSAR?

A SUSAR is a serious adverse reaction to a medicinal product that is both unexpected (not consistent with the product’s Investigator’s Brochure or Summary of Product Characteristics) and suspected to be related to the investigational medicinal product. Reporting SUSARs promptly helps protect clinical trial subjects and ensures regulatory compliance.

Why Use EudraVigilance for SUSAR Reporting?

EudraVigilance is the centralized database used by the EMA to collect and manage information on adverse reactions to medicines that are authorized or being studied in the EU. It enables:

• Standardized electronic submission of individual case safety reports (ICSRs)
• Real-time access for national competent authorities (NCAs)
• Better analysis and signal detection for emerging safety concerns

Sponsors conducting trials in the EU are legally obligated to report SUSARs electronically to the EMA through this platform.

Step 1: Register with EudraVigilance:

To begin reporting, organizations must be registered with EMA’s EudraVigilance system. The process includes:

1. Obtaining an EMA Account through the EMA Account Management portal
2. Submitting an organization registration request in the EMA’s SPOR system
3. Receiving an EV Organization Identifier (OrgID) and registration in XEVMPD
4. Completing a testing and training phase with EudraVigilance for access to production systems

Step 2: Understanding the ICSR Format:

ICSRs submitted to EudraVigilance must conform to the ICH E2B(R3) standard. Key fields include:

• Patient demographic information
• Details of the adverse event
• Suspected drug and its dosage regimen
• Reporter details (sponsor contact, investigator)

Reporting entities must also assign a Worldwide Unique Case Identification Number (e.g., EU-CTR-CT-YYYY-XXXXXX).

Step 3: Timeline for Reporting SUSARs:

According to GMP guidelines and EU Directive 2001/20/EC, the following timelines apply:

• 7 calendar days for fatal or life-threatening SUSARs (followed by a complete report within 8 additional days)
• 15 calendar days for all other SUSARs

These timelines begin from the date the sponsor becomes aware of the event.

Step 4: Submitting ICSRs via EudraVigilance Gateway or Web Interface:

Sponsors may report SUSARs via:

• EudraVigilance Gateway: A secure electronic transmission route for bulk submission of ICSRs
• EudraVigilance Web Interface (EVWEB): An online portal suitable for low-volume users or manual entry

EVWEB provides real-time validation and feedback on the status of submissions, including acknowledgments and error reports.

Step 5: Validation and Acknowledgment:

Once submitted, each SUSAR ICSR is validated against EMA’s business rules. Possible outcomes include:

• ACKNOWLEDGED: Successfully validated and stored
• WARNING: Non-critical issues flagged
• REJECTED: Critical errors detected (must be corrected and resubmitted)

Step 6: Data Sharing with NCAs and Ethics Committees:

Once ICSRs are validated, they are automatically made available to the National Competent Authorities (NCAs) and European Ethics Committees involved in the clinical trial. Sponsors must also ensure that relevant updates are communicated to investigators and subjects when necessary.

Best Practices for Effective SUSAR Reporting:

• Use standardized MedDRA coding for adverse reactions
• Ensure data completeness and internal validation before submission
• Regularly train pharmacovigilance staff on EudraVigilance procedures
• Maintain alignment with Stability Studies data for investigational products
• Keep audit trails for all reported SUSARs as per GVP Module VI

Regulatory Framework Supporting SUSAR Reporting:

The following EMA and EU regulations govern SUSAR reporting:

• Regulation (EU) No 536/2014 on clinical trials
• Directive 2001/20/EC and 2005/28/EC
• GVP Module VI: Management and Reporting of Adverse Reactions to Medicinal Products

Automating Pharmacovigilance Compliance:

Many large sponsors and CROs implement pharmacovigilance automation platforms integrated with EudraVigilance for batch upload of ICSRs, automated validation checks, and analytics dashboards. This ensures reduced human error, compliance with EMA requirements, and real-time visibility into safety data trends.

Training and Resources for EudraVigilance Users:

• EMA’s EudraVigilance Training Modules (required before accessing the production system)
• ICSR Technical Documentation and EV User Manual
• XEVMPD training for managing product dictionary data
• Controlled Vocabulary (ISO IDMP) updates

Conclusion:

Reporting SUSARs to the EMA via EudraVigilance is a critical requirement in the EU clinical trial landscape. Sponsors must ensure accurate, timely, and validated submission of ICSRs to remain compliant with EMA regulations. Through a combination of technical preparedness, staff training, and automation where feasible, organizations can maintain the highest standards in pharmacovigilance while prioritizing patient safety. Familiarity with EudraVigilance’s submission process is essential for any organization conducting trials within the EU.